Summary

Eligibility
for males ages 18 years and up (full criteria)
Location
at UC Davis UCSD UCSF
Dates
study started
completion around
Principal Investigator
by Mack Roach (ucsf)
Headshot of Mack Roach
Mack Roach

Description

Summary

RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells.

PURPOSE: This randomized phase III trial studies androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer.

Official Title

Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Details

Keywords

Prostate Cancer, adenocarcinoma of the prostate, stage I prostate cancer, stage IIA prostate cancer, stage IIB prostate cancer, stage III prostate cancer, Prostatic Neoplasms, radiation therapy, Whole-pelvic radiotherapy (WPRT)

Eligibility

Locations

Lead Scientist at University of California Health

  • Mack Roach (ucsf)
    Professor, Radiation Oncology, School of Medicine. Authored (or co-authored) 306 research publications

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Radiation Therapy Oncology Group
ID
NCT01368588
Phase
Phase 3 research study
Study Type
Interventional
Participants
About 2592 people participating
Last Updated